Cited by 202Cancer Genomics and DiagnosticsSarcoma Diagnosis and TreatmentGenomic variations and chromosomal abnormalities

Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

Open access
Peneder, Peter, Stütz, Adrian M., Surdez, Didier, Krumbholz, Manuela, Semper, Sabine, Chicard, Mathieu, Sheffield, Nathan C., Pierron, Gaelle +28 more·2021·Nature Communications

Abstract

Sequencing of cell-free DNA in the blood of cancer patients (liquid biopsy) provides attractive opportunities for early diagnosis, assessment of treatment response, and minimally invasive disease monitoring. To unlock liquid biopsy analysis for pediatric tumors with few genetic aberrations, we introduce an integrated genetic/epigenetic analysis method and demonstrate its utility on 241 deep whole-genome sequencing profiles of 95 patients with Ewing sarcoma and 31 patients with other pediatric sarcomas. Our method achieves sensitive detection and classification of circulating tumor DNA in peripheral blood independent of any genetic alterations. Moreover, we benchmark different metrics for cell-free DNA fragmentation analysis, and we introduce the LIQUORICE algorithm for detecting circulating tumor DNA based on cancer-specific chromatin signatures. Finally, we combine several fragmentation-based metrics into an integrated machine learning classifier for liquid biopsy analysis that exploits widespread epigenetic deregulation and is tailored to cancers with low mutation rates. Clinical associations highlight the potential value of cfDNA fragmentation patterns as prognostic biomarkers in Ewing sarcoma. In summary, our study provides a comprehensive analysis of circulating tumor DNA beyond recurrent genetic aberrations, and it renders the benefits of liquid biopsy more readily accessible for childhood cancers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23445-w

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Application of WGS in longitudinal MRD detection remains challenging due to relatively high sequencing cost and lower sensitivity compared to NGS-based ctDNA panel detection.

    “Nevertheless, the application of WGS in longitudinal MRD detection remains challenging due to its relatively high sequencing cost and lower sensitivity, compared to NGS-based ctDNA panel detection.”

    From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [17]

    The Results section (page not provided) states that deep cfDNA whole-genome sequencing is costly as a routine diagnostic assay. It does not establish that WGS has lower sensitivity than NGS-based ctDNA panels for longitudinal MRD detection; its reported sensitivity comparison is against other genetic methods, not targeted panels. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [71]Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https://arxiv.org/abs/1303.3997 (2013). · arXiv

Cited by

Sorted by citations

Authors
Peneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., Sheffield, N. C., Pierron, G., Lapouble, E., Tötzl, M., Ergüner, B., Barreca, D., Rendeiro, A. F., Agaimy, A., Boztug, H., Engstler, G., Dworzak, M., Bernkopf, M., Taschner-Mandl, S., Ambros, I. M., Myklebost, O., Marec-Bérard, P., Burchill, S. A., Brennan, B., Strauss, S. J., Whelan, J., Schleiermacher, G., Schaefer, C., Dirksen, U., Hutter, C., Boye, K., Ambros, P. F., Delattre, O., Metzler, M., Bock, C., & Tomazou, E. M.
Affiliations
  • St. Anna Children's Cancer Research Institute (AT)
  • Inserm (FR)
  • Universitätsklinikum Erlangen (DE)
  • University of Virginia (US)
  • Institut Curie (FR)
  • Austrian Academy of Sciences (AT)
  • St Anna Children's Hospital (AT)
  • Oslo University Hospital (NO)
  • St James's University Hospital (GB)
  • Royal Manchester Children's Hospital (GB)
  • University College Hospital (GB)
  • Essen University Hospital (DE)
Corresponding author
  • Bock, Christoph
  • Tomazou, Eleni M.
Venue
Nature Communications
Published
2021-05-28
Volume
12
Issue
1
Pages
3230-3230
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3165287952
Cited by
200
References
82
Citations by year
2026: 26 · 2025: 39 · 2024: 38 · 2023: 45 · 2022: 39 · 2021: 12 · 2020: 1
FWCI
13.63
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Kreftforeningen
  • European Commission (HORIZON2020, 602856)
  • Vienna Science and Technology Fund (LS18-049)
  • Austrian Science Fund (V 506, I 2798)
  • Oesterreichische Nationalbank (17876)
  • Ligue Contre le Cancer
  • Deutsche Krebshilfe (#108128, 70112018, DKH 108128, 70113419)
  • H2020 European Research Council (679146)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
liquid biopsy, cell-free DNA, childhood cancer, Ewing sarcoma, pediatric sarcoma, low mutational burden, cfDNA fragmentation, chromatin signatures, epigenetic dysregulation, prognostic factors, machine learning classifiers
MeSH terms
Whole Genome Sequencing, Liquid Biopsy, Circulating Tumor DNA, Adolescent, Adult, Bone Neoplasms, Child, Child, Preschool, DNA Mutational Analysis, Female, Humans, Infant, Male, Middle Aged, Mutation, Sarcoma, Ewing, Biomarkers, Tumor, Case-Control Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review